crocin-1What was measured
Measured, with no finding
104 endpoints
Show what was measuredHide what was measured
Beck Anxiety Inventory score
decreases, b -4.35; 95% CI -5.94, -2.75
Not recorded as a finding: No node for Beck Anxiety Inventory (the listed anxiety nodes are HAM-A and a pooled composite).
After 8-week intervention, crocin significantly decreased Beck Depression Inventory (b - 6.66; 95% CI, - 9.88, - 3.45; P < 0.0001), Beck Anxiety Inventory (b - 4.35; 95% CI, - 5.94, - 2.75; P < 0.0001), general health questionnaire (b - 4.45; 95% CI, - 7.68, - 1.22; P = 0.008) and Pittsburgh Sleep Quality Index (b - 2.73; 95% CI, - 3.74, - 1.73; P < 0.0001) in patients under MMT, compared with the placebo.
PMID 30795785 · both readings recorded this
Beck Anxiety Inventory
decreases, p = 0.0001
Beck Anxiety Inventory (b - 4.35; 95% CI, - 5.94, - 2.75; P < 0.0001)
PMID 30795785 · one of two readings recorded this
Beck Depression Inventory
decreases, p = 0.0001
crocin significantly decreased Beck Depression Inventory (b - 6.66; 95% CI, - 9.88, - 3.45; P < 0.0001)
PMID 30795785 · one of two readings recorded this
General Health Questionnaire score
decreases, b -4.45; 95% CI -7.68, -1.22, p = 0.008
Not recorded as a finding: No node for the General Health Questionnaire.
After 8-week intervention, crocin significantly decreased Beck Depression Inventory (b - 6.66; 95% CI, - 9.88, - 3.45; P < 0.0001), Beck Anxiety Inventory (b - 4.35; 95% CI, - 5.94, - 2.75; P < 0.0001), general health questionnaire (b - 4.45; 95% CI, - 7.68, - 1.22; P = 0.008) and Pittsburgh Sleep Quality Index (b - 2.73; 95% CI, - 3.74, - 1.73; P < 0.0001) in patients under MMT, compared with the placebo.
PMID 30795785 · both readings recorded this
General health questionnaire
decreases, p = 0.008
general health questionnaire (b - 4.45; 95% CI, - 7.68, - 1.22; P = 0.008)
PMID 30795785 · one of two readings recorded this
International Index of Erectile Function score
increases, b 4.98; 95% CI 2.08, 7.88, p = 0.001
Not recorded as a finding: No node for the International Index of Erectile Function (the listed sexual-function nodes are FSFI and a pooled composite).
Crocin also significantly improved International Index of Erectile Functions (b 4.98; 95% CI, 2.08, 7.88; P = 0.001) rather than placebo.
PMID 30795785 · both readings recorded this
International Index of Erectile Function
increases, p = 0.001
Crocin also significantly improved International Index of Erectile Functions (b 4.98; 95% CI, 2.08, 7.88; P = 0.001)
PMID 30795785 · one of two readings recorded this
Pittsburgh Sleep Quality Index
decreases, p = 0.0001
Pittsburgh Sleep Quality Index (b - 2.73; 95% CI, - 3.74, - 1.73; P < 0.0001)
PMID 30795785 · one of two readings recorded this
Total cholesterol (TC)
decreases
TC levels in the saffron group were 0.19 lower and 0.11 fold lower in crocin group than in the placebo group
PMID 32013614 · one of two readings recorded this
Total cholesterol (TC)
decreases
TC levels in the saffron group were 0.19 lower and 0.11 fold lower in crocin group than in the placebo group
PMID 32013614 · one of two readings recorded this
Blood glucose
no effect
The blood glucose levels did not significantly differ from the control group
PMID 32013614 · one of two readings recorded this
HDL-C, LDL-C, total cholesterol, triglycerides and blood glucose, saffron and crocin pooled versus placebo
increases, HDL-C 0.01 fold higher in the crocin group than placebo
Not recorded as a finding: no estimate is reported anywhere
A pooled analysis using a model for random-effects showed that HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo.
PMID 32013614 · one of two readings recorded this
HDL-C
increases
HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo
PMID 32013614 · one of two readings recorded this
HDL-C
increases
HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo
PMID 32013614 · one of two readings recorded this
LDL-C
decreases
LDL-C levels in the saffron group reduced by 0.51 and 0.04 fold in the crocin group versus the placebo
PMID 32013614 · one of two readings recorded this
LDL-C
decreases
LDL-C levels in the saffron group reduced by 0.51 and 0.04 fold in the crocin group versus the placebo
PMID 32013614 · one of two readings recorded this
serum HDL-C, LDL-C, total cholesterol and TG, pooled fold-differences for saffron and crocin groups versus placebo
HDL-C 0.01 fold higher in the crocin group than placebo
Not recorded as a finding: a direction is stated and the estimate does not support it
A pooled analysis using a model for random-effects showed that HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo.
PMID 32013614 · one of two readings recorded this
Triglycerides (TG)
decreases
TG level in saffron group was 0.04 lower and 0.02 fold lower in crocin than the control group
PMID 32013614 · one of two readings recorded this
Triglycerides (TG)
decreases
TG level in saffron group was 0.04 lower and 0.02 fold lower in crocin than the control group
PMID 32013614 · one of two readings recorded this
Total cholesterol (TC)
decreases, p = 0.01
TC (WMD: -4.64 mg/l, 95 % CI, -8.19, -1.09; p = 0.010)
PMID 32951748 · one of two readings recorded this
Fasting blood glucose (FBG) change versus intervention duration (meta-regression)
modulates, p = 0.019
Meta-regression analysis indicated a linear relationship between the duration of intervention and significant change in FBG (p = 0.019)
PMID 32951748 · one of two readings recorded this
Fasting blood glucose (FBG)
decreases, p = 0.019
FBG (WMD: -6.52 mg/l, 95 % CI, -11.96, -1.08; p = 0.019)
PMID 32951748 · one of two readings recorded this
Fasting blood glucose (FBG)
no effect
crocin supplementation did not significantly change FBG in trials that used low dose intervention
PMID 32951748 · one of two readings recorded this
HDL-C
no effect, p = 0.872
Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels
PMID 32951748 · one of two readings recorded this
LDL-C
no effect, p = 0.161
Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels
PMID 32951748 · one of two readings recorded this
LDL-C
decreases
LDL-C levels in trials that used high dose intervention and trials that conducted on subjects with metabolic disorders
PMID 32951748 · one of two readings recorded this
Serum triglycerides (TG)
no effect, p = 0.144
Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels
PMID 32951748 · one of two readings recorded this
Triglycerides (TG)
decreases
crocin supplementation could beneficially have effect on TG level only when trial duration less than 12 weeks
PMID 32951748 · one of two readings recorded this
Blood urea nitrogen (BUN)
no effect, p = 0.9, n = 40
BUN (mg/dL) | 47.32 ± 27.83 | 46.65 ± 22.79 | −0.67 ± 16.79 | 0.86 | 45.06 ± 12.34 | 43.78 ± 13.01 | −1.28 ± 10.78 | 0.62 | 0.90
PMID 36209091 · one of two readings recorded this
BMI, SBP, DBP (mercury sphygmomanometer, seated) and serum TGF-beta (ELISA) between-group change
decreased in crocin group versus placebo, none statistically significant
Not recorded as a finding: Direction word ('decreased') with a statement of non-significance but no estimate; one-sided, so no_effect is not supportable (direction_stated_but_not_significant).
Moreover, the mean BMI, SBP, and DBP and median serum TGF-β levels decreased in the crocin group compared with the placebo group but none of these changes were statistically significant.
PMID 36209091 · one of two readings recorded this
Body mass index (BMI)
no effect, p = 0.3, n = 40
BMI (kg/m2) | 27.21 ± 3.86 | 27.02 ± 3.95 | −0.46 ± 1.25 | 0.12 | 27.26 ± 3.34 | 27.16 ± 3.44 | −0.10 ± 0.56 | 0.49 | 0.30
PMID 36209091 · one of two readings recorded this
C-reactive protein (CRP)
no effect, p = 0.94, n = 40
CRP (mg/dL) | 5.00 ± 0.50 | 5.00 ± 1.00 | 0.00 ± 1.50 | 0.79 | 5.00 ± 0.00 | 5.00 ± 0.00 | 0.00 ± 0.00 | 0.46 | 0.94
PMID 36209091 · one of two readings recorded this
Diastolic blood pressure (DBP)
no effect, p = 0.16, n = 40
DBP (mm Hg) | 81.44 ± 16.46 | 77.19 ± 9.66 | −4.25 ± 17.02 | 0.33 | 75.33 ± 12.31 | 78.13 ± 8.87 | −2.80 ± 8.39 | 0.22 | 0.16
PMID 36209091 · one of two readings recorded this
Erythrocyte sedimentation rate (ESR)
no effect, p = 0.15, n = 40
ESR (mm/hr) | 17.00 ± 28.00 | 22.00 ± 11.00 | 1.00 ± 15.50 | 0.98 | 17.50 ± 18.00 | 14.50 ± 17.00 | −2.50 ± 7.75 | 0.05 | 0.15
PMID 36209091 · one of two readings recorded this
Estimated glomerular filtration rate (eGFR)
no effect, p = 0.47, n = 40
eGFR (mL/min/1.73 m2) | 61.00 ± 20.00 | 67.00 ± 36.00 | 0.00 ± 22.50 | 0.13 | 58.00 ± 39.25 | 62.00 ± 44.75 | 0.00 ± 9.75 | 0.94 | 0.47
PMID 36209091 · one of two readings recorded this
fasting blood sugar and HbA1c (HPLC) change
increased in both groups, greater in placebo, not significant
Not recorded as a finding: Sentence names neither compound nor arm; increase in both groups, greater in placebo, not significant.
Although this increase was greater in the placebo group, these changes were not significant.
PMID 36209091 · one of two readings recorded this
Fasting blood sugar (FBS)
no effect, p = 0.26, n = 40
FBS (mg/dL) | 140.52 ± 36.71 | 146.24 ± 49.62 | 5.71 ± 38.58 | 0.51 | 136.58 ± 57.17 | 159.21 ± 62.62 | 22.63 ± 54.04 | 0.08 | 0.26
PMID 36209091 · one of two readings recorded this
Glycated hemoglobin (HbA1c)
no effect, p = 0.31, n = 40
HbA1c (%) | 6.87 ± 0.67 | 7.03 ± 0.83 | 0.16 ± 0.56 | 0.22 | 7.32 ± 1.04 | 7.87 ± 1.69 | 0.48 ± 0.98 | 0.05 | 0.31
PMID 36209091 · one of two readings recorded this
serum creatinine (Jaffe), eGFR (4-variable MDRD), CRP, ESR (Westergren), TC, HDL-C, LDL-C, BUN between-group changes
no effect, changes not significantly different between the two groups
Not recorded as a finding: Agentless sentence that names neither compound nor arm, so it does not support a claim on its own (quote_not_self_supporting).
Mean values for changes in TC, HDL, LDL, BUN, and as well as median values for changes in SCr, ESR, CRP, urine microalbumin, uACR, and eGFR were not significantly different between the two groups.
PMID 36209091 · one of two readings recorded this
Serum creatinine (SCr)
no effect, p = 0.59, n = 40
SCr (mg/dL) | 1.20 ± 0.40 | 1.10 ± 0.50 | 0.00 ± 0.30 | 0.41 | 1.10 ± 0.40 | 1.10 ± 0.70 | 0.00 ± 0.22 | 0.75 | 0.59
PMID 36209091 · one of two readings recorded this
Serum HDL-C
no effect, p = 0.84, n = 40
Serum HDL-C (mg/dL) | 41.62 ± 9.93 | 45.95 ± 12.28 | 4.33 ± 14.36 | 0.18 | 48.68 ± 14.61 | 52.05 ± 14.41 | 3.37 ± 15.57 | 0.36 | 0.84
PMID 36209091 · one of two readings recorded this
Serum LDL-C
no effect, p = 0.43, n = 40
Serum LDL-C (mg/dL) | 64.51 ± 23.44 | 63.95 ± 33.57 | −0.56 ± 26.58 | 0.92 | 79.21 ± 53.38 | 71.89 ± 61.40 | − 7.32 ± 26.41 | 0.24 | 0.43
PMID 36209091 · one of two readings recorded this
Serum TGF-β
no effect, p = 0.21, n = 40
Serum TGF-β (ng/mL) | 17.10 ± 0.80 | 16.92 ± 0.85 | −0.21 ± 1.21 | 0.56 | 16.93 ± 1.98 | 17.29 ± 0.94 | 0.33 ± 2.40 | 0.35 | 0.21
PMID 36209091 · one of two readings recorded this
Serum total cholesterol (TC)
no effect, p = 0.26, n = 40
Serum TC (mg/dL) | 133.24 ± 29.49 | 141.81 ± 40.97 | 8.57 ± 33.22 | 0.25 | 157.89 ± 58.85 | 156.21 ± 64.61 | −1.68 ± 22.33 | 0.75 | 0.26
PMID 36209091 · one of two readings recorded this
Serum triglycerides (TG)
decreases, p = 0.03, n = 40
Serum TG (mg/dL) | 157.89 ± 84.69 | 133.79 ± 43.21 | −24.10 ± 74.57 | 0.17 | 143.52 ± 63.89 | 169.33 ± 69.71 | 25.81 ± 61.48 | 0.06 | 0.03*
PMID 36209091 · one of two readings recorded this
Systolic blood pressure (SBP)
no effect, p = 0.34, n = 40
SBP (mm Hg) | 150.25 ± 18.08 | 143.13 ± 26.07 | −7.12 ± 14.95 | 0.07 | 138.20 ± 42.45 | 141.13 ± 18.71 | 2.93 ± 38.35 | 0.77 | 0.34
PMID 36209091 · one of two readings recorded this
urine albumin-to-creatinine ratio (uACR), primary endpoint; serum creatinine (Jaffe), eGFR (MDRD), CRP, ESR, TC, HDL-C, LDL-C, BUN
no effect, changes not significantly different between the two groups
Not recorded as a finding: The only sentence reporting these does not name the compound (agentless, 'the two groups'); uACR also has no outcome node.
Mean values for changes in TC, HDL, LDL, BUN, and as well as median values for changes in SCr, ESR, CRP, urine microalbumin, uACR, and eGFR were not significantly different between the two groups.
PMID 36209091 · one of two readings recorded this
urine albumin-to-creatinine ratio (uACR), primary outcome, spot morning urine
no effect, median changes in uACR not significantly different between the two groups
Not recorded as a finding: No node: the listed urinary albumin excretion node requires a timed collection in ug/min, not a spot-urine ratio. Sentence is agentless and names no arm.
Mean values for changes in TC, HDL, LDL, BUN, and as well as median values for changes in SCr, ESR, CRP, urine microalbumin, uACR, and eGFR were not significantly different between the two groups.
PMID 36209091 · one of two readings recorded this
Urine albumin-to-creatinine ratio (uACR)
no effect, p = 0.98, n = 40
UACR (mg/g) | 161.00 ± 250.8 | 152.5 ± 188.8 | 10.5 ± 151 | 0.46 | 186.85 ± 240.8 | 157.5 ± 243.8 | 16 ± 143 | 0.58 | 0.98
PMID 36209091 · one of two readings recorded this
Urine microalbumin
no effect, p = 0.718, n = 40
Urine micro albumin (mg/dL) | 185.0 ± 232.5 | 128.5 ± 287.4 | 34 ± 141.55 | 0.26 | 181.00 ± 316.80 | 141.00 ± 131.3 | 11.50 ± 248.75 | 0.98 | 0.718
PMID 36209091 · one of two readings recorded this
Creatinine
increases
increased creatinine levels (WMD 0.24, 95%CI 0.17, 0.32)
PMID 37778521 · one of two readings recorded this
Creatinine
decreases
creatinine (WMD -0.12, 95%CI -0.19, -0.05)
PMID 37778521 · one of two readings recorded this
Aspartate aminotransferase (AST)
decreases
Saffron powdered plant decreased AST (WMD -1.19, 95%CI -2.24, -0.13)
PMID 37778521 · one of two readings recorded this
Body mass index (BMI)
increases
increased BMI (WMD 0.56, 95%CI 0.07, 1.05)
PMID 37778521 · one of two readings recorded this
Fasting blood glucose (FBG)
decreases
FBG (WMD -14.10, 95%CI -22.91, -5.30)
PMID 37778521 · one of two readings recorded this
Fasting blood glucose (FBG)
decreases
FBG (WMD -26.90, 95%CI -38.87, -14.93)
PMID 37778521 · one of two readings recorded this
Glycated hemoglobin (HbA1c)
decreases
crocin decreased HbA1c (WMD -0.43, 95%CI -0.66, -0.20)
PMID 37778521 · one of two readings recorded this
Glycated hemoglobin (HbA1c)
decreases
saffron extract decreased HbA1c (WMD -0.35, 95%CI -0.65, -0.06)
PMID 37778521 · one of two readings recorded this
HbA1c, fasting blood glucose (FBG), systolic blood pressure and creatinine in type 2 diabetes, pooled as before-after mean differences
decreases, crocin HbA1c WMD -0.43 (95%CI -0.66, -0.20); FBG WMD -14.10 (95%CI -22.91, -5.30)
Not recorded as a finding: the result compares a group with itself, not with a control
Saffron powdered plant decreased AST (WMD -1.19, 95%CI -2.24, -0.13), but increased BMI (WMD 0.56, 95%CI 0.07, 1.05); saffron extract decreased HbA1c (WMD -0.35, 95%CI -0.65, -0.06), FBG (WMD -26.90, 95%CI -38.87, -14.93), creatinine (WMD -0.12, 95%CI -0.19, -0.05), and total cholesterol (WMD -9.29, 95%CI -18.25, -0.33); and crocin decreased HbA1c (WMD -0.43, 95%CI -0.66, -0.20), FBG (WMD -14.10, 95%CI -22.91, -5.30), and systolic blood pressure (WMD -8.18, 95%CI -12.75, -3.61), but increased creatinine levels (WMD 0.24, 95%CI 0.17, 0.32).
PMID 37778521 · one of two readings recorded this
HbA1c, fasting blood glucose (FBG), systolic blood pressure and creatinine in type-2 diabetes, weighted mean differences (before-after)
decreases, crocin: HbA1c WMD -0.43; FBG WMD -14.10; systolic blood pressure WMD -8.18; creatinine WMD 0.24
Not recorded as a finding: the result compares a group with itself, not with a control
Saffron powdered plant decreased AST (WMD -1.19, 95%CI -2.24, -0.13), but increased BMI (WMD 0.56, 95%CI 0.07, 1.05); saffron extract decreased HbA1c (WMD -0.35, 95%CI -0.65, -0.06), FBG (WMD -26.90, 95%CI -38.87, -14.93), creatinine (WMD -0.12, 95%CI -0.19, -0.05), and total cholesterol (WMD -9.29, 95%CI -18.25, -0.33); and crocin decreased HbA1c (WMD -0.43, 95%CI -0.66, -0.20), FBG (WMD -14.10, 95%CI -22.91, -5.30), and systolic blood pressure (WMD -8.18, 95%CI -12.75, -3.61), but increased creatinine levels (WMD 0.24, 95%CI 0.17, 0.32).
PMID 37778521 · one of two readings recorded this
Systolic blood pressure
decreases
systolic blood pressure (WMD -8.18, 95%CI -12.75, -3.61)
PMID 37778521 · one of two readings recorded this
Total cholesterol
decreases
total cholesterol (WMD -9.29, 95%CI -18.25, -0.33)
PMID 37778521 · one of two readings recorded this
Change in total antioxidant capacity (TAC)
increases, p = 0.01
The mean ± SD of TAC change was 0.03 ± 0.07 mM vs. - 0.03 ± 0.09 mM in intervention and placebo groups, respectively (Time × group effect P: 0.01; effect size: 0.10)
PMID 37917350 · one of two readings recorded this
CVLT-II-delay
increases, p = 0.01
CVLT-II-delay (P < 0.01; effect size: 0.29)
PMID 37917350 · one of two readings recorded this
CVLT-II
increases, p = 0.01
The time effect of intervention on the California Verbal Learning Test second edition (CVLT-II) (P < 0.01; effect size: 0.29)
PMID 37917350 · one of two readings recorded this
Glutathione reductase (GR) activity
decreases, p = 0.01
the time effect of intervention on GR activity was significant and decreasing in both groups (P < 0.01; effect size: 0.20)
PMID 37917350 · one of two readings recorded this
serum total antioxidant capacity (colorimetric kit) in multiple sclerosis patients after 12 weeks of crocin-selenium nanoparticles versus placebo
TAC change 0.03 +/- 0.07 mM versus -0.03 +/- 0.09 mM, time x group effect P 0.01, effect size 0.10, p = 0.01
Not recorded as a finding: the intervention held more than the compound
The mean ± SD of TAC change was 0.03 ± 0.07 mM vs. - 0.03 ± 0.09 mM in intervention and placebo groups, respectively (Time × group effect P: 0.01; effect size: 0.10).
PMID 37917350 · one of two readings recorded this
Symbol Digit Modalities Test (SDMT)
increases, p = 0.01
the Symbol Digit Modalities Test (SDMT) (P < 0.01; effect size: 0.18)
PMID 37917350 · one of two readings recorded this
total antioxidant capacity (colorimetric kit), glutathione reductase activity, malondialdehyde and BICAMS cognition in multiple sclerosis
TAC change 0.03 ± 0.07 mM versus -0.03 ± 0.09 mM, intervention versus placebo, p = 0.01
Not recorded as a finding: the intervention held more than the compound
The mean ± SD of TAC change was 0.03 ± 0.07 mM vs. - 0.03 ± 0.09 mM in intervention and placebo groups, respectively (Time × group effect P: 0.01; effect size: 0.10).
PMID 37917350 · one of two readings recorded this
HOMA-IR
decreases, p = 0.002
β - 0.18; 95% CI, - 0.29, - 0.07; P = 0.002
PMID 38294505 · one of two readings recorded this
Anxiety
no effect, p = 0.05
nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05)
PMID 38294505 · one of two readings recorded this
Depression
no effect, p = 0.05
nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05)
PMID 38294505 · one of two readings recorded this
fasting plasma glucose (FPG), insulin, HOMA-IR and serum hs-CRP in smokers after 3 months of 30 mg/day crocin versus placebo
FPG beta -3.27 mg/dL (95% CI -5.23, -1.31), p = 0.002
Not recorded as a finding: the direction is carried only as a signed number
Also in the secondary outcomes, fasting plasma glucose (FPG), insulin, and homeostasis model of assessment-insulin resistance (HOMA-IR) levels did indicate a significant difference by Cro intervention (β - 3.27 mg/dL; 95% CI, - 5.23, - 1.31; P = 0.002; β - 0.76 μIU/mL; 95% CI, - 1.38, - 0.15; P = 0.01; β - 0.18; 95% CI, - 0.29, - 0.07; P = 0.002), respectively.
PMID 38294505 · one of two readings recorded this
Fasting plasma glucose
decreases, p = 0.002
β - 3.27 mg/dL; 95% CI, - 5.23, - 1.31; P = 0.002
PMID 38294505 · one of two readings recorded this
hs-CRP
decreases, p = 0.03
hs-CRP) (β - 0.72 mg/L; 95% CI, - 1.37, - 0.07; P = 0.03)
PMID 38294505 · one of two readings recorded this
Insulin
decreases, p = 0.01
β - 0.76 μIU/mL; 95% CI, - 1.38, - 0.15; P = 0.01
PMID 38294505 · one of two readings recorded this
Nicotine dependence
no effect, p = 0.05
nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05)
PMID 38294505 · one of two readings recorded this
serum high-sensitivity C-reactive protein, fasting plasma glucose, insulin and HOMA-IR in smokers after 3 months of crocin 30 mg/day versus placebo (Avicel)
decreases, hs-CRP beta -0.72 mg/L; 95% CI -1.37, -0.07, p = 0.03
Not recorded as a finding: the supporting sentence never names the compound
There were also significant reductions in serum levels of high-sensitivity C-reactive protein (hs-CRP) (β - 0.72 mg/L; 95% CI, - 1.37, - 0.07; P = 0.03), compared with the placebo.
PMID 38294505 · one of two readings recorded this
Anxiety (Beck anxiety scale)
decreases, p = 0.01
within-group comparisons showed crocin significantly decreased anxiety (p-value= 0.01)
PMID 38306888 · one of two readings recorded this
anxiety on the Beck anxiety questionnaire
decreases, within-group decrease, p = 0.01
Not recorded as a finding: No outcome node for Beck Anxiety Inventory, and the reported result is a within-group comparison.
In addition, within-group comparisons showed crocin significantly decreased anxiety (p-value= 0.01).
PMID 38306888 · one of two readings recorded this
Beck anxiety questionnaire score, within-group comparison
decreases, within-group decrease in anxiety, p = 0.01, p = 0.01
Not recorded as a finding: Within-group change only, and no node for Beck anxiety inventory.
In addition, within-group comparisons showed crocin significantly decreased anxiety (p-value= 0.01).
PMID 38306888 · one of two readings recorded this
hs-CRP
decreases, p = 0.01
supplementation with crocin for 8 weeks significantly lowered hs-CRP levels (p-value= 0.01)
PMID 38306888 · one of two readings recorded this
serum malondialdehyde (MDA), 8 weeks
no effect
Not recorded as a finding: Sentence 'did not affect serum MDA and NO' does not say whether it is a between-arm or within-arm test and gives no estimate.
However, crocin did not affect serum MDA and NO after 8 weeks of intervention.
PMID 38306888 · one of two readings recorded this
serum malondialdehyde
no effect, did not affect serum MDA and NO after 8 weeks
Not recorded as a finding: Assay (TBARS or HPLC) not stated and no estimate; the node requires the assay recorded with each finding. Sentence also pools MDA with NO.
However, crocin did not affect serum MDA and NO after 8 weeks of intervention.
PMID 38306888 · one of two readings recorded this
Serum MDA
no effect
crocin did not affect serum MDA and NO after 8 weeks of intervention
PMID 38306888 · one of two readings recorded this
serum nitric oxide
no effect, did not affect serum MDA and NO after 8 weeks
Not recorded as a finding: No node for serum nitric oxide.
However, crocin did not affect serum MDA and NO after 8 weeks of intervention.
PMID 38306888 · one of two readings recorded this
Serum NO
no effect
crocin did not affect serum MDA and NO after 8 weeks of intervention
PMID 38306888 · one of two readings recorded this
C-reactive protein (CRP)
decreases, p = 0.008
crocin supplementation significantly reduced c-reactive protein (CRP) levels (SMD: -0.50; 95%CI: -0.86 to -0.13; p = 0.008)
PMID 39632602 · one of two readings recorded this
erythrocyte sedimentation rate (ESR), pooled meta-analysis
no effect
Not recorded as a finding: Node requires the Westergren method; abstract does not state the method.
Overall effect size showed that crocin intake failed to change the erythrocyte sedimentation rate (ESR) and malondialdehyde (MDA) levels significantly.
PMID 39632602 · one of two readings recorded this
Erythrocyte sedimentation rate (ESR)
no effect
Overall effect size showed that crocin intake failed to change the erythrocyte sedimentation rate (ESR) and malondialdehyde (MDA) levels significantly
PMID 39632602 · one of two readings recorded this
Inflammatory markers
decreases
The effect of crocin on inflammatory markers was greater in a dose ≥ 30 mg/day and an intervention duration ≥ 12 weeks
PMID 39632602 · one of two readings recorded this
Interleukin-6 (IL-6)
decreases, p = 0.03
interleukin-6 (IL-6) (SMD: -3.52; 95%CI: -6.84 to -0.20; p = 0.03)
PMID 39632602 · one of two readings recorded this
Malondialdehyde (MDA)
no effect
Overall effect size showed that crocin intake failed to change the erythrocyte sedimentation rate (ESR) and malondialdehyde (MDA) levels significantly
PMID 39632602 · one of two readings recorded this
Total antioxidant capacity (TAC)
increases, p = 0.002
crocin supplementation led to a significant increase in total antioxidant capacity (TAC) (SMD: 1.48; 95%CI: 0.52 to 2.43; p = 0.002)
PMID 39632602 · one of two readings recorded this
Tumor necrosis factor-α (TNF-α)
decreases, p = 0.001
tumor necrosis factor-α (TNF-α) (SMD: -1.96; 95%CI: -2.72 to -1.19; p < 0.001)
PMID 39632602 · one of two readings recorded this
Change in heart rate from baseline
decreases, p = 0.008
The changes in heart rate from baseline to 6 months showed a significant difference as the mean difference of -4.00 (95 %CI, -6.95 to -1.05) bpm (P = 0.008)
PMID 39889867 · one of two readings recorded this
Mean change in NT-proBNP
unclear, p = 0.017
At 6 months, there were significant differences in the mean change of N-terminal pro-brain natriuretic peptide (NT-pro BNP) between the groups (3.06 [-25.18-6.95] vs. 3.06 [-4.85-24.98] pg/ml; P = 0.017)
PMID 39889867 · one of two readings recorded this
proportion of patients with a drop in left ventricular ejection fraction (LVEF) of at least 10 % from baseline until 6 months, anthracycline-induced cardiotoxicity
7.2 % (7/97) in the crocin group versus 17.7 % (17/96) in the placebo group, p = 0.027
Not recorded as a finding: this platform holds no node for the endpoint
The incidence of the primary efficacy outcome was 7.2 % (7/97) in the crocin group and 17.7 % (17/96) in the placebo group (P = 0.027).
PMID 39889867 · one of two readings recorded this
proportion of patients with a drop in left ventricular ejection fraction of at least 10% from baseline to 6 months, crocin tablets versus placebo during anthracycline chemotherapy
7.2% (7/97) crocin versus 17.7% (17/96) placebo, p = 0.027
Not recorded as a finding: this platform holds no node for the endpoint
The incidence of the primary efficacy outcome was 7.2 % (7/97) in the crocin group and 17.7 % (17/96) in the placebo group (P = 0.027).
PMID 39889867 · one of two readings recorded this
Proportion with LVEF drop of at least 10 % from baseline
decreases, p = 0.027, n = 193
The incidence of the primary efficacy outcome was 7.2 % (7/97) in the crocin group and 17.7 % (17/96) in the placebo group (P = 0.027)
PMID 39889867 · one of two readings recorded this
Lipid profile and fasting blood glucose (FBG)
no effect, n = 28
no significant difference was detected among the other biochemical factors (lipid profile and FBG) between two groups
PMID 40817397 · one of two readings recorded this
serum IL-2, IL-10, VEGF and INF γ, sandwich chemiluminescence assay, in metabolic syndrome
decreases, significantly reduced after Crocin treatment, P < 0.05
Not recorded as a finding: this platform holds no node for the endpoint
Our results indicated that inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment.
PMID 40817397 · one of two readings recorded this
serum IL-2, IL-10, VEGF and interferon-gamma, sandwich chemiluminescence assay, before and after 8 weeks of crocin 15 mg versus placebo in metabolic syndrome
decreases, significantly reduced (P < 0.05) after Crocin treatment
Not recorded as a finding: this platform holds no node for the endpoint
Our results indicated that inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment.
PMID 40817397 · one of two readings recorded this
Serum inflammatory cytokines (IL-2, IL-10, VEGF, INF γ)
decreases, p = 0.05, n = 28
inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment
PMID 40817397 · one of two readings recorded this